ArticleEMBO reports2016
CRISPR/Cas9-induced disruption of gene expression in mouse embryonic brain and single neural stem cells in vivo.
Article in EMBO reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 83 citations in OpenAlex.
- An evolutionary genomic perspective on preterm birth, genome editing, and pregnancy in the human species.Frontiers in genome editing · 2026Review
- Morphoregulatory ADD3 underlies glioblastoma growth and formation of tumor-tumor connections.Life science alliance · 2025Article
- Article
- New uses for an old technique: live imaging on the slice organ culture to study reproductive processes†.Biology of reproduction · 2024Article
- Microinjection of the CRISPR/Cas9 editing system through the germ pore of a wheat microspore induces mutations in the target Ms2 gene.Molecular biology reports · 2024Article
- The growth factor EPIREGULIN promotes basal progenitor cell proliferation in the developing neocortex.The EMBO journal · 2024Article
- Manipulation of the nuclear envelope-associated protein SLAP during mammalian brain development affects cortical lamination and exploratory behavior.Biology open · 2024Article
- Extracellular vesicle-mediated delivery of CRISPR/Cas9 ribonucleoprotein complex targeting proprotein convertase subtilisin-kexin type 9 (Pcsk9) in primary mouse hepatocytes.Journal of extracellular vesicles · 2024Article
- Advanced Techniques Using In Vivo Electroporation to Study the Molecular Mechanisms of Cerebral Development Disorders.International journal of molecular sciences · 2023Review
- DOT1L activity affects neural stem cell division mode and reduces differentiation and ASNS expression.EMBO reports · 2023Article
- Recent Genome-Editing Approaches toward Post-Implanted Fetuses in Mice.Biotech (Basel (Switzerland)) · 2023Review
- Targeted Microinjection and Electroporation of Primate Cerebral Organoids for Genetic Modification.Journal of visualized experiments : JoVE · 2023Article
- In vivo processing of digital information molecularly with targeted specificity and robust reliability.Science advances · 2022Article
- Recent advances in the use of CRISPR/Cas for understanding the early development of molecular gaps in glial cells.Frontiers in cell and developmental biology · 2022Review
- Advances in approaches to study cell-type specific cortical circuits throughout development.Frontiers in cellular neuroscience · 2022Review
- Advancing Drug Discovery for Neurological Disorders Using iPSC-Derived Neural Organoids.International journal of molecular sciences · 2021Review
- CRISPR/Cas-Dependent and Nuclease-FreeHuman gene therapy · 2021Review
- SNAP23 deficiency causes severe brain dysplasia through the loss of radial glial cell polarity.The Journal of cell biology · 2021Article
- Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.Theranostics · 2021Review
- CRISPR/Cas: a potential gene-editing tool in the nervous system.Cell regeneration (London, England) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have applied the CRISPR/Cas9 system in vivo to disrupt gene expression in neural stem cells in the developing mammalian brain. Two days after in utero electroporation of a single plasmid encoding Cas9 and an appropriate guide RNA (gRNA) into the embryonic neocortex of Tis21::GFP knock-in mice, expression of GFP, which occurs specifically in neural stem cells committed to neurogenesis, was found to be nearly completely (≈ 90%) abolished in the progeny of the targeted cells. Importantly, upon in utero electroporation directly of recombinant Cas9/gRNA complex, near-maximal efficiency of disruption of GFP expression was achieved already after 24 h. Furthermore, by using microinjection of the Cas9 protein/gRNA complex into neural stem cells in organotypic slice culture, we obtained disruption of GFP expression within a single cell cycle. Finally, we used either Cas9 plasmid in utero electroporation or Cas9 protein complex microinjection to disrupt the expression of Eomes/Tbr2, a gene fundamental for neocortical neurogenesis. This resulted in a reduction in basal progenitors and an increase in neuronal differentiation. Thus, the present in vivo application of the CRISPR/Cas9 system in neural stem cells provides a rapid, efficient and enduring disruption of expression of specific genes to dissect their role in mammalian brain development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.